Pharmacy

With drug costs rising, workforce shortages intensifying, and new therapies reshaping care delivery, pharmacy leaders are facing more complexity — and responsibility — than ever. That’s why Becker’s is bringing together hundreds of health plan leaders to transform the industry.…

AbbVie is acquiring Gilgamesh Pharmaceuticals’ lead drug candidate bretisilocin, used to treat moderate to severe major depressive disorder, for up to $1.2 billion.  Bretisilocin is a psychedelic compound that targets the 5-HT2A receptor and releases serotonin, according to an Aug.…

OptumRx, a UnitedHealth subsidiary, is tracking three new drugs this year: 

Heading into 2026, pharmacy leaders expect to see operations transformed, including shifts in Medicare pricing reform, artificial intelligence and expanding clinical responsibilities.  Here are responses from five pharmacy leaders who were asked: How do you anticipate your pharmacy functions will…

Krystal Biotech has paused enrollment of its trial testing the intratumoral form of its experimental cancer drug KB707, citing a shift in development. The decision comes ahead of a scheduled end-of-phase-2 meeting with the FDA in October, during which the…

The FDA suspended the license for vaccine manufacturer Valneva’s chikungunya vaccine following reports of serious adverse events.  The decision halts all shipping and sales of the vaccine in the U.S., effective immediately, according to an Aug. 25 news release from…

The FDA has accepted Stealth BioTherapeutics’ resubmission of its new drug application for elamipretide, a treatment for Barth syndrome.  The agency set an earlier review target date of Sept. 26, ahead of the Feb. 15 deadline, according to an Aug.…

A study has found that adults with obesity taking GLP-1 receptor agonists may face significantly lower risk of developing certain cancers.  The cohort study was led by researchers from the Indiana School of Medicine in Indianapolis and the University of…

More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics​​ expand resources and care for underserved communities.  By requiring pharmaceutical companies to offer deep discounts on outpatient drugs, the program has become a hallmark…

The rising cost of medications is turning into a financial gut punch for hospitals, with pharmaceutical spending driving tens of millions of dollars in losses across health systems.  In the first half of 2025, New York City-based Memorial Sloan Kettering…